Loading…
Crescent Biopharma, Inc. is projected to rise to $15.42 by 2027, a +7% move from its current price of $14.47. CBIO is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $13.87 | $14.47 | $15.09 | -0.02% |
| Aug 3 | $13.63 | $14.46 | $15.35 | -0.05% |
| Aug 4 | $13.45 | $14.46 | $15.55 | -0.07% |
| Aug 5 | $13.30 | $14.46 | $15.72 | -0.09% |
| Aug 6 | $13.16 | $14.45 | $15.87 | -0.12% |
| Aug 7 | $13.04 | $14.45 | $16.01 | -0.14% |
| Aug 8 | $12.93 | $14.45 | $16.14 | -0.17% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $12.93 | $14.45 | $16.14 | -0.17% |
| Week 2 | $12.33 | $14.42 | $16.87 | -0.33% |
| Week 3 | $11.88 | $14.40 | $17.44 | -0.50% |
| Week 4 | $11.52 | $14.37 | $17.94 | -0.66% |
| Week 5 | $11.20 | $14.35 | $18.38 | -0.83% |
| Week 6 | $10.92 | $14.33 | $18.79 | -0.99% |
| Week 7 | $10.67 | $14.30 | $19.17 | -1.16% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Crescent Biopharma, Inc. is a biotechnology company that researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.
The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc.
The company was founded in 2024 and is headquartered in Waltham, Massachusetts.
Crescent Biopharma, Inc. (CBIO) is the asset with a current price of $14.77. It has a market capitalization of $545.94M and ranks 2966 by market cap. The price outlook is bullish over the longer horizon, with forecast averages rising from $14.77 in 2026 to $26.54 in 2030 and further to $119.19 in 2050, implying substantial upside and ROI reaching as high as 707%.
A major floor 27.9% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 28.3% above — a clean break opens room to run.
A major ceiling 86.5% above — clearing it would confirm fresh momentum.
Key CBIO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CBIO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $15.53 | Sell | $15.22 | Sell |
| MA 10 | $15.85 | Sell | $15.60 | Sell |
| MA 20 | $16.00 | Sell | $16.06 | Sell |
| MA 50 | $17.47 | Sell | $16.91 | Sell |
| MA 100 | $17.63 | Sell | $16.76 | Sell |
| MA 200 | $14.88 | Sell | $17.07 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 39.12 | Neutral |
| Stoch RSI (14) | 32.88 | Neutral |
| CCI (20) | -122.75 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.06 | Sell |
| ROC (12) | -7.66 | Sell |
| Bollinger %B (20,2) | 0.08 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.48 | Sell |
| Awesome (5,34) | -1.18 | Sell |
| Ultimate (7,14,28) | 39.83 | Neutral |
| Momentum (10) | -0.28 | Sell |
| Aroon Osc (25) | -96.00 | Sell |
| Hull MA (9) | 14.68 | Sell |
| ADX (14) | 14.59 | Neutral |
| ATR (14) | 0.66 | Info |
The 30-day technical picture is NEUTRAL. RSI (14) is 40. The 50-day simple moving average (SMA50) is $17.62 and the 200-day simple moving average (SMA200) is $14.84. The near-term chart shows support at $14.75 and resistance at $18.56. The 30-day price range spans from a low of $11.07 to a high of $19.70. Annualized volatility is 80%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $8.94 | $14.47 | $16.99 | 0% | Neutral | |
| $11.70 | $15.42 | $21.81 | +7% | Neutral | |
| $12.84 | $17.71 | $26.42 | +22% | Bullish | |
| $15.80 | $22.66 | $35.23 | +57% | Bullish | |
| $16.87 | $25.04 | $40.27 | +73% | Bullish | |
| $17.10 | $26.20 | $43.40 | +81% | Bullish | |
| $17.33 | $27.36 | $46.52 | +89% | Bullish | |
| $16.02 | $26.02 | $45.30 | +80% | Bullish | |
| $16.95 | $28.29 | $50.34 | +96% | Bullish | |
| $20.55 | $35.22 | $63.92 | +143% | Bullish | |
| $24.85 | $48.19 | $94.95 | +233% | Bullish | |
| $48.50 | $107.78 | $238.66 | +645% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $8.94 | $14.47 | $16.90 | +0.00% |
| September 2026 | $11.56 | $13.89 | $17.32 | -4.00% |
| October 2026 | $11.66 | $14.16 | $17.94 | +1.94% |
| November 2026 | $11.05 | $13.53 | $17.37 | -4.42% |
| December 2026 | $10.60 | $13.09 | $16.99 | -3.30% |
Click any year to see its month-by-month CBIO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Crescent Biopharma, Inc.'s 2026 outlook centres on $14.47, within a $8.94 to $16.99 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, CBIO could reach as high as $21.81, with a base case around $15.42 and support toward $11.70 — roughly +7% from $14.47. A consolidation phase looks the most probable path here.
Expect CBIO to range from $12.84 to $26.42 through 2028. The $17.71 average target implies a +22% move from current prices. That is up +15% on the projected 2027 average. Momentum favours further upside here.
The CBIO price prediction for 2029 points to an average of $22.66 (low $15.80, high $35.23) — a potential gain of +57% on today's $14.47. Buyers look set to stay in control over this stretch.
In 2030, CBIO is projected to trade between $16.87 and $40.27, averaging $25.04 — a potential gain of +73% from today's $14.47. That is up +10% on the projected 2029 average. Momentum favours further upside here.
Crescent Biopharma, Inc.'s 2031 outlook centres on $26.20, within a $17.10 to $43.40 range. That is up +5% on the projected 2030 average. That marks a +81% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, CBIO could reach as high as $46.52, with a base case around $27.36 and support toward $17.33 — roughly +89% from $14.47. Momentum favours further upside here.
Expect CBIO to range from $16.02 to $45.30 through 2033. The $26.02 average target implies a +80% move from current prices. That is -5% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
The CBIO price prediction for 2034 points to an average of $28.29 (low $16.95, high $50.34) — a potential gain of +96% on today's $14.47. Momentum favours further upside here.
In 2035, CBIO is projected to trade between $20.55 and $63.92, averaging $35.22 — a potential gain of +143% from today's $14.47. That is up +24% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Crescent Biopharma, Inc.'s 2040 outlook centres on $48.19, within a $24.85 to $94.95 range. That is up +37% on the projected 2035 average. That marks a +233% change versus current levels. Momentum favours further upside here.
By 2050, CBIO could reach as high as $238.66, with a base case around $107.78 and support toward $48.50 — roughly +645% from $14.47. Buyers look set to stay in control over this stretch.
Investing $1,000 in CBIO today (≈ 69.1085 CBIO) could be worth
$7,448.7
+$6,448.7 (+645%) by 2050 · US Dollar
Based on the average projected CBIO price of $107.78 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CBIOwould be worth at today's price.
$1,000 invested in CBIO on Jul 31, 2025 (≈ 80.515297 CBIO) would be worth
$1,165.06
+$165.06 (+16.5%) today · 1.17× · US Dollar
Based on a CBIO entry price of $12.42 vs. today's $14.47.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $16.3 | $887.73 | -11.2% |
| 1 month ago | $17.08 | $847.19 | -15.3% |
| 3 months ago | $18.07 | $800.77 | -19.9% |
| 6 months ago | $9.82 | $1,473.52 | +47.4% |
| 1 year ago | $12.42 | $1,165.06 | +16.5% |
| All time (5.0y) ago | $201 | $71.99 | -92.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CBIO forecast.
Our base-case forecast reaches $29.00 around 2035.
Implied market cap at $29.00: $1.08B
The multi-year forecast depicts a bullish trajectory overall, with a transition from neutral to bullish sentiment in the later years. The 2026 forecast shows an average of $14.77 (min $8.94, max $17.39) with ROI 0% and NEUTRAL sentiment; by 2027 the average is $15.98 (min $12.05, max $22.78) with ROI 8.2% and NEUTRAL sentiment. From 2028 onward, sentiment turns BULLISH and the averages rise to $18.48 (2028), $23.93 (2029), $26.54 (2030; ROI 79.7%), $27.64 (2031), $29.05 (2032), $27.59 (2033), $30.10 (2034), and $38.32 (2035) with progressively higher ROIs through the mid-2030s.
In 2040 the average is $52.02 (ROI 252.2%), and in 2050 the average is $119.19 (ROI 707%). The forecast implies strong upside potential over the long run, but these are estimates and not guarantees; outcomes depend on factors that can influence clinical progress and market dynamics.
Tap a question to reveal the answer.
Avg $26.54, min $17.65, max $43.21; ROI 79.7%; sentiment BULLISH.
Forecasts show a bullish trajectory in the later years, with 2030 avg $26.54 and 2050 avg $119.19 and ROI up to 707%; early years are neutral (e.g., 2026 avg $14.77, ROI 0%). These are estimates, not guarantees.
2040 max $104.35; reaching around $100 is within the forecast range.
Current price $14.77; Market cap $545.94M.
Sentiment NEUTRAL; RSI (14) 40; SMA50 $17.62; SMA200 $14.84; Support $14.75; Resistance $18.56; 30-day range low $11.07, high $19.70.
Crescent Biopharma, Inc. Community Discussion
0Share your Crescent Biopharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.